Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Cash (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Change in Cash for 4 consecutive years, with $153.8 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 151.65% to $153.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.1 million through Dec 2025, up 168.15% year-over-year, with the annual reading at $72.1 million for FY2025, 168.15% up from the prior year.
  • Change in Cash for Q4 2025 was $153.8 million at Day One Biopharmaceuticals, up from $7.7 million in the prior quarter.
  • The five-year high for Change in Cash was $183.1 million in Q3 2024, with the low at -$297.8 million in Q4 2024.
  • Average Change in Cash over 4 years is -$5.5 million, with a median of -$4.1 million recorded in 2023.
  • Peak annual rise in Change in Cash hit 252.43% in 2024, while the deepest fall reached 2764.81% in 2024.
  • Over 4 years, Change in Cash stood at -$35.6 million in 2022, then soared by 70.8% to -$10.4 million in 2023, then tumbled by 2764.81% to -$297.8 million in 2024, then skyrocketed by 151.65% to $153.8 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $153.8 million, $7.7 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.